Core One in Talks With Multiple Companies to Supply Psilocybin
Core One in Talks With Multiple Companies to Supply Psilocybin
VANCOUVER, BC / ACCESSWIRE / May 5, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6), (WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that it is in discussions with several pharmaceutical laboratories and research organizations to supply them with active pharmaceutical ingredient (API) psilocybin to meet their psychedelic research needs.
不列颠哥伦比亚省温哥华/ACCESSWIRE/2023年5月5日/ Core One实验室公司(CSE：凉爽的)(OTCQB：CLABF)(法兰克福：LD6)，(WKN：A3CSSU)(“公司“或”核心一“)很高兴地宣布，它正在与几个制药实验室和研究机构讨论向他们提供活性药物成分(API)裸盖菇素，以满足他们的迷幻研究需求。
Scientific interest in psilocybin has grown exponentially in recent years, with many high profile clinical trials showing enormous potential for the psychedelic compound in treating various mental health and neurological disorders, such as anxiety, depression, obsessive-compulsive disorder, various addictions, as well as Alzheimer's and Parkinson's diseases, to name a few[1]. Promising results from many of these trials, though still in early stages and requiring further study[2], have given rise to rapid growth of a psychedelic industry and the emergence of many public and private entities engaged in research with psychedelics intended for medical use.
近年来，科学家对裸盖菇素的兴趣呈指数级增长，许多备受瞩目的临床试验表明，这种迷幻化合物在治疗各种精神健康和神经疾病方面具有巨大的潜力，例如焦虑、抑郁、强迫症、各种成瘾以及阿尔茨海默氏症和帕金森氏症等。其中许多试验的结果令人振奋，虽然仍处于早期阶段，需要进一步研究[2]，但已促使迷幻药行业迅速发展，并出现了许多公共和私人实体，它们从事用于医疗用途的迷幻药的研究。
With the psychedelics industry still in its infancy, Core One has been taking significant steps to position itself as a leading full-cycle psychedelics supply chain solution. The Company has the potential to produce its own psychedelic compounds at a Good Manufacturing Practices ("GMP") facility, while, in collaboration with its partners, also manufactures and could supply its high-quality and cost-effective products to licensed clients in Canada.
由于迷幻药行业仍处于初级阶段，Core One一直在采取重大措施，将自己定位为领先的全周期迷幻药供应链解决方案。该公司有潜力在良好的制造规范(GMP)设施中生产自己的迷幻化合物，同时与其合作伙伴合作，也生产并能够向加拿大的特许客户提供其高质量和高成本效益的产品。
By streamlining a psychedelic supply chain and structuring itself as a vertically integrated business, Core One could control the production process of its products and develop an uninterrupted revenue stream. Management regards a robust and reliable supply chain as a key component in establishing its business clientele and capturing a large share of the medicinal and clinical psychedelics' market.
通过精简迷幻供应链并将自己构建为垂直整合的业务，Core One可以控制其产品的生产过程，并发展不间断的收入流。管理层认为，强大而可靠的供应链是建立其商业客户并占领药物和临床迷幻药市场的很大份额的关键组成部分。
With the future landscape of the global psychedelic space, which reached $4.2 billion in 2022, is expected to transform drastically into an enormous to $8.31 billion industry in 2027[3], Core One is eager to capitalize on this opportunity and become one of the largest suppliers in a rapidly expanding psychedelic market.
全球迷幻领域的未来前景在2022年达到42亿美元，预计到2027年将彻底转变为一个规模巨大、价值83.1亿美元的行业[3]，Core One渴望利用这个机会，成为快速扩张的迷幻市场的最大供应商之一。
"Engaging in talks with multiple companies to supply them with psychedelic compounds demonstrates how far the Company has come since initial research and development stages to where it is now. Embarking on the sales aspect of our corporate strategy keeps us ahead of the pack when it comes to being a leading supplier of medicinal psychedelics. We believe that our ability to continue to execute on our goals demonstrates to shareholders and other pharmaceutical companies why Core One is positioned to disrupt the medical industry when it comes to mental health and addiction treatments," stated Joel Shacker, Core One Labs CEO.
Core One Labs首席执行官乔尔·沙克表示：“与多家公司进行谈判，向他们供应迷幻药化合物，这表明公司从最初的研发阶段到现在已经取得了多大的进步。开始我们公司战略的销售方面的工作，使我们在成为一家领先的药物迷幻药供应商方面保持领先。我们相信，我们有能力继续执行我们的目标，向股东和其他制药公司表明，为什么Core One在心理健康和成瘾治疗方面处于颠覆医疗行业的地位。”
About Core One Labs Inc.
Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology.
Core One Labs Inc.简介
Core One Labs是一家生命科学生物技术研发公司，专注于通过迷幻化合物的开发和生产、迷幻辅助治疗的进步以及新型递送系统技术的集成，将迷幻药物推向市场。
The Company has a multi-faceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.
该公司拥有多方面的业务方法，并合并了几个互补的业务和部门，以确立其作为快速增长和新兴的迷幻药市场领域的行业领先者的地位。
Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its 100% owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other 100% owned subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.
Core One通过其全资子公司Vocan BioTechnologies Inc.开发了一种使用工程菌生产裸盖菇素的专有系统，并申请了专利保护。它还持有4项临时专利，用于开发针对神经和精神健康障碍的迷幻药物配方，由其100%拥有的子公司Akome Biotech Ltd.拥有，并拥有3项临时专利，由其另一家100%拥有的子公司Awaded Biosciences Inc.拥有，用于开发裸盖菇素和裸盖菇素生产方法的其他合成技术。
In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics the Company intends to integrate a roll out of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.
除了开发迷幻剂和迷幻化合物外，Core One还持有四家医疗诊所的股份，这四家诊所维护着一个超过275,000名患者的综合数据库。通过其诊所，该公司打算整合其与迷幻技术相关的知识产权的推出，并参与推进基于迷幻药物的精神健康障碍治疗。
Core One Labs Inc.
Joel Shacker
Chief Executive Officer
Core One实验室公司
乔尔·谢克
首席执行官
FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-888-452-6731
如需更多信息，请联系：
邮箱：Info@core1Labs.com
1-888-452-6731
Cautionary Disclaimer Statement:
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
谨慎免责声明：
加拿大证券交易所没有对本新闻稿内容的充分性或准确性进行审查，也不承担任何责任。
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
本新闻稿中的信息包含前瞻性陈述，这些陈述基于截至本新闻稿发布之日的假设。这些陈述反映了管理层当前的估计、信念、意图和期望。它们并不是未来业绩的保证。公司提醒，所有前瞻性陈述本身都是不确定的，实际表现可能会受到许多重大因素的影响，其中许多因素不是公司所能控制的。这些因素包括但不限于：与该公司有限的经营历史有关的风险和不确定因素，以及遵守严格监管规定的必要性。因此，实际和未来的事件、条件和结果可能与前瞻性信息中明示或暗示的估计、信念、意图和预期大不相同。除非适用的证券法规另有要求，否则公司没有义务公开更新或修改前瞻性信息。
In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.
此外，裸盖菇素目前是《联合国宪章》第三类药物。《受管制药物和物质法》(加拿大)，拥有《公约》规定的物质是刑事犯罪。《受管制药物和物质法》(加拿大)没有处方或授权的。加拿大卫生部尚未批准裸盖菇素作为任何适应症的药物。Core One不直接或间接参与在其运营的司法管辖区非法销售、生产或分销迷幻药物。虽然Core One认为迷幻物质可以用于治疗某些医疗疾病，但它并不主张娱乐用途的迷幻物质合法化。CORE One不涉及致幻物质，除非在经批准的监管框架内进行的实验室和临床试验。
[1]
[1]
[2]
[2]
[3]
[3]
SOURCE: Core One Labs Inc.
资料来源：Core One实验室公司
译文内容由第三方软件翻译。